Review
Medicine, General & Internal
Jun Xu, Jianguo Zhao, Jianfang Wang, Caiping Sun, Xiaoling Zhu
Summary: This meta-analysis suggests that a higher pretreatment LDH level is significantly associated with worse overall survival and shorter progression-free survival in melanoma patients receiving anti-PD1/PD-L1 monotherapy.
Review
Oncology
Wen Wen, Yong Zhang, Hua Zhang, Yingshuang Chen
Summary: PD-L1/PD-1 inhibitors have shown effective and tolerable outcomes in advanced hepatocellular carcinoma patients. Additionally, the combination of PD-L1/PD-1 inhibitors with anti-VEGF agents leads to more clinical improvements compared to monotherapy.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Oncology
Yao Yang, Dongbo Chen, Bigeng Zhao, Liying Ren, Rui Huang, Bo Feng, Hongsong Chen
Summary: Positive PD-L1 expression is associated with a significantly improved objective response rate (ORR) in advanced hepatocellular carcinoma (HCC) patients treated with anti-PD-1/PD-L1-based therapies. This feature can help to identify HCC patients who will benefit most from PD-1/PD-L1 inhibitors.
Review
Biotechnology & Applied Microbiology
Huan Wang, Youchao Xiao, Xingguang Ren, Dahai Wan
Summary: This meta-analysis found that increased PD-L1 expression is associated with poorer overall survival in patients with glioblastoma (GBM). The study also revealed an association between PD-L1 mRNA expression and the status of isocitrate dehydrogenase (IDH). Overall, increased PD-L1 expression may serve as a promising prognostic biomarker for GBM.
Article
Oncology
Chien-Hsu Chen, Mu-Yao Tsai, Ping-Chia Chiang, Ming-Tse Sung, Hao-Lun Luo, Jau-Ling Suen, Eing-Mei Tsai, Po-Hui Chiang
Summary: The study revealed that PD-L1 CPS >= 10 in UTUC was associated with adverse pathological features and independently predicted worse cancer-specific and overall survival.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Plant Sciences
Zi-Xuan Gao, Zhan-Sheng Zhang, Jia Qin, Ming -Zhu Zhang, Jin-Lan Cao, Ying-Ying Li, Meng-Qing Wang, Dong Fang, Song-Qiang Xie
Summary: This study evaluated the antitumor effects of aucubin on hepatocellular carcinoma (HCC) and investigated its synergistic effects with cisplatin. The results showed that aucubin inhibited tumor growth and suppressed PD-L1 expression through the Akt/beta-catenin signaling pathway. Aucubin also enhanced the antitumor activity of cisplatin by blocking PD-L1 expression.
Review
Immunology
Quanqing Tang, Shihao Li, Gaozhen Huang, Hongwei Liu
Summary: Urothelial carcinoma (UC) is a common malignant tumor. Platinum-based chemotherapy has been the standard treatment for metastatic UC, but immune checkpoint inhibitors (ICIs) offer hope for patients unfit for platinum therapy.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Oncology
Panpan Kong, Huan Yang, Qing Tong, Xiaogang Dong, Mamumaimaitijiang-Abula Yi, Dong Yan
Summary: PD-L1, CD86, and CD206 are involved in the occurrence and development of liver cancer and immune regulation, suggesting their potential role as biomarkers and therapeutic targets for prognosis assessment of liver cancer.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Hui Zhou, Anhong Li, Chuan Li, Mingyong Wu, Dan Jin, Mingcai Shui
Summary: CBX8 plays a crucial role in the occurrence and development of various tumors, including cervical cancer. High expression of CBX8 in cervical cancer tissues is associated with advanced FIGO stage and poor prognosis. Co-expression of CBX8 and PD-L1 can better predict the postoperative survival of patients with cervical cancer and serve as an independent prognostic factor.
Review
Biochemistry & Molecular Biology
Fabio Scirocchi, Lidia Strigari, Alessandra Di Filippo, Chiara Napoletano, Angelica Pace, Hassan Rahimi, Andrea Botticelli, Aurelia Rughetti, Marianna Nuti, Ilaria Grazia Zizzari
Summary: This study investigates the correlation between soluble programmed death ligand-1 (sPD-L1) and survival in cancer patients undergoing immunotherapy. The results show that high levels of sPD-L1 are associated with worse overall survival and progression-free survival in cancer patients treated with immunotherapy. Specifically, in non-small cell lung cancer patients, higher levels of sPD-L1 are correlated with poorer survival. sPD-L1 could serve as a non-invasive biomarker that is easily measurable in the blood, helping to select cancer patients before immunotherapy and improve treatment efficacy while avoiding unnecessary treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Ke Su, Lu Guo, Kun He, Mingyue Rao, Jianwen Zhang, Xiaoli Yang, Weihong Huang, Tao Gu, Ke Xu, Yanlin Liu, Jing Wang, Jiali Chen, Zhenying Wu, Lanxin Hu, Hao Zeng, Hongyan Li, Jian Tong, Xueting Li, Yue Yang, Hanlin Liu, Yaoyang Xu, Zunyuan Tan, Xue Tang, Xunjie Feng, Siyu Chen, Binbin Yang, Hongping Jin, Lechuan Zhu, Bo Li, Yunwei Han
Summary: The study demonstrates that PD-L1(+) CTCs can be used as a predictive biomarker in HCC patients receiving PD-1 inhibitors combined with IMRT and antiangiogenic therapy in order to evaluate treatment efficacy.
FRONTIERS IN ONCOLOGY
(2022)
Review
Multidisciplinary Sciences
Limeng Wu, Canhua Jiang, Zhihui Zhu, Yao Sun, Tao Zhang
Summary: This study conducted a meta-analysis to evaluate the association of programmed cell death-ligand 1 (PD-L1) expression with clinicopathological features and prognosis in patients with salivary gland carcinoma (SGC). The results showed that positive PD-L1 expression was significantly associated with certain clinicopathological features and poor overall survival and disease-free survival in SGC patients.
Review
Oncology
David Johnson, Brigette B. Y. Ma
Summary: The upregulation of the PD-1/PD-L1 pathway is a possible immune-evasion mechanism in Epstein-Barr virus-associated nasopharyngeal cancer (NPC). Therapeutic targeting of this pathway is actively researched in NPC, with multiple monoclonal antibodies currently under evaluation in clinical settings. Combinatorial strategies involving cytotoxic chemotherapy, radiotherapy, and other immunotherapeutic agents are also being explored in clinical trials for NPC.
Review
Immunology
Huizhen Cao, Tianyu Wu, Xue Zhou, Shuyang Xie, Hongfang Sun, Yunxiao Sun, Youjie Li
Summary: Leukemia cells induce immunosuppression of the bone marrow microenvironment, preventing the immune system from clearing tumor cells. The PD-1/PD-L1 axis acts as a significant mechanism for tumor cells to evade immune surveillance. The development of drugs targeting PD-1/PD-L1 in leukemia is still at the clinical-trial stage.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Jae-Hoon Chung, Chung-Un Lee, Dong-Hyeon Lee, Wan Song
Summary: This study found that positive PD-L1 expression in tumor-infiltrating immune cells (TICs) is significantly associated with poorer recurrence-free survival in urothelial carcinoma (UC) patients with variant histology.